Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Contact: Study coordinator (Kun Wang, PhD)Contact: Principal Investigator (Kun Wang, PhD)Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Li Ling, PhD)Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Principal Investigator (Herui Yao, PhD)Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Shusen Wang, PhD)Contact: Principal Investigator (Shusen Wang, PhD)The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Contact: Study coordinator (Mei Huang, MD)The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Ying Lin, PhD)Shantou Central Hospital, Shantou, Guangdong, China
Contact: Study coordinator (Zhiyong Wu, MD)Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
Contact: Study coordinator (Caiwen Du, PhD)Shenzhen People's Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Ruilian Xu, Master)Affiliated Hospital of Guangdong Medical University, Zhangjiang, Guangdong, China
Contact: Study coordinator (Ying Zhang, MD)Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China
Contact: Study coordinator (Peijian Peng, PhD)Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China
Contact: Study coordinator (Yongkui Lu, MD)Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Study coordinator (Quchang Ouyang, PhD)
Study leads
Herui Yao, PhD
Study Chair
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shusen Wang, PhD
Principal Investigator
Sun Yat-sen University
Kun Wang, PhD
Principal Investigator
Guangdong Provincial People's Hospital
Peijian Peng, PhD
Principal Investigator
Fifth Subsidiary Sun Yat-sen University Hospital
Li Ling, PhD
Principal Investigator
Public Health Institute of Sun Yat-sen University
Yongkui Lu, MD
Principal Investigator
Affiliated Cancer Hospital of Guangxi Medical University
Quchang Ouyang, PhD
Principal Investigator
Hunan Cancer Hospital
Ying Lin, phD
Principal Investigator
First Affiliated Hospital, Sun Yat-Sen University
Ying Zhang, MD
Principal Investigator
Affiliated Hospital of Guangdong Medical University
Mei Huang, MD
Principal Investigator
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Zhiyong Wu, MD
Principal Investigator
Shantou Central Hospitalv
Cai'wen Du, PhD
Principal Investigator
Chinese Academy of Medical Sciences